Shanghai Fosun Pharmaceutical : OVERSEAS REGULATORY ANNOUNCEMENT (H SHARES)

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The following sets out the ''Announcement in Relation to Receipt of Approval for Drug Clinical Trial by a Subsidiary'' published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the ''Company'') on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Chen Qiyu

Chairman

Shanghai, the People's Republic of China

13 October 2020

As at the date of this announcement, the executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang and Mr. Wu Yifang; the non-executive directors of the Company are Mr. Xu Xiaoliang, Mr. Gong Ping, Mr. Pan Donghui and Mr. Zhang Houlin; and the independent non-executive directors of the Company are Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin, Ms. Li Ling and Mr. Tang Guliang.

• for identification purposes only

Stock code: 600196	Stock abbreviation: Fosun Pharma Announcement No.: Lin 2020-155
Bond code: 136236	Bond abbreviation: 16 Fosun 01
Bond code: 143020	Bond abbreviation: 17 Fosun 01
Bond code: 143422	Bond abbreviation: 18 Fosun 01
Bond code: 155067	Bond abbreviation: 18 Fosun 02
Bond code: 155068	Bond abbreviation: 18 Fosun 03

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Announcement in Relation to Receipt of Approval for Drug

Clinical Trial by a Subsidiary

The board of directors of the Company and all members of the Board warrant that this announcement does not contain any false information, misleading statement or material omission, and severally and jointly accept full responsibility for the truthfulness, accuracy and completeness of the contents herein contained.

I. Overview

Recently, Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.* (上海復 星醫藥產業發展有限公司 ) ("Fosun Pharmaceutical Industrial"), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "Company"), has received the approval for clinical trial for Avatrombopag Maleate Tablet (the "Investigational New Drug") for Immune Thrombocytopenia (ITP) in adult patients from the National Medical Products Administration. Fosun Pharmaceutical Industrial intends to start the phase III clinical of the Investigational New Drug of the above-mentioned indication in the PRC (excluding Hong Kong and Macau Special Administrative Region and Taiwan region, the same below) recently when preparations are done.

II. Research on the Investigational New Drug

In March 2019, Fosun Pharmaceutical Industrial was granted the exclusive distribution right of the Investigational New Drug (including the exclusive right to register and develop for sale) in the Region (i.e. Chinese Mainland and the Hong Kong Special Administrative Region) by AkaRx Inc. ("AkaRx") , a U.S. based company and a subsidiary of Swedish Orphan Biovitrum AB. AkaRx is still the right owner of the Investigational New Drug in the Region. AkaRx shall be responsible for supplying products to Fosun

1

Pharmaceutical Industrial for the sales in the Region.

The Investigational New Drug is a chemical drug. As of the date of this announcement, the Investigational New Drug for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure has been marketed in the United States, the European Union, and China, and the Investigational New Drug for the treatment of immune thrombocytopenia (ITP) has been marketed in the United States. In addition, an international multi-center phase III clinical trial for the use of the Investigational New Drug for cancer chemotherapy-induced thrombocytopenia (CIT) has been completed recently, the preliminary trial results did not meet the composite primary endpoint. Accordingly, Fosun Pharmaceutical Industrial will combine the analysis of the clinical research trials and results to further evaluate and determine the clinical development strategy, optimize the clinical trial design and determine the drug application strategy in PRC.

According to the latest data from IQVIA MIDASTM provided by IQVIA, a global leading provider of professional information and strategic consulting services for the pharmaceutical and health industry, the global sales of Avatrombopag Maleate Tablet in 2019 amounted to approximately US$ 3.43 million.

As at September 2020, the cumulative R&D investment of the Group (ie, the Company and its holding subsidiaries/units) in the Investigational New Drug was approximately RMB105.99 million (unaudited, including license transfer fees) at this stage.

III. Risk Warning

There are certain risks in the R&D of new drugs based on our experience. For example, clinical trials may be terminated due to issues such as safety and/or efficacy.

As required by the relevant laws and regulations in the PRC, the Investigational New Drug is subject to a series of clinical studies and the approval from the national drug evaluation authority in the PRC before it can be marketed.

The R&D and marketing of new drugs is a long-term task involving various uncertainties. Investors should be aware of the investment risks.

Announcement is hereby given.

The board of directors of

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

13 October 2020

2